. 2022 Feb 26;49(9):3257–3268. doi: 10.1007/s00259-022-05741-9

Table 4.

Rate and type of events in the overall population and stratified by clinical setting

Clinical setting	Events	Type of Events
Overall (n = 176)	44.9% (n = 79/176)	23.9% (n = 42/176)	17.6% (n = 31/176)	3.4% (n = 6/176)
Subgroup 1 (n = 76)	35.5% (n = 27/76)	25% (n = 19/76)	10.5% (n = 8/76)	0.0% (n = 0/76)
Subgroup 2 (n = 76)	52.6% (n = 40/76)	21.1% (n = 16/76)	26.3% (n = 20/76)	5.3% (n = 4/76)
Subgroup 3 (n = 24)	50.0% (n = 12/24)	29.2% (n = 7/24)	12.5% (n = 3/24)	8.3% (n = 2/24)

Clinical setting

Events

Type of Events

PSA recurrence after therapy*

Radiological progression**

Death

% (n)

Overall

(n = 176)

44.9%

(n = 79/176)

23.9%

(n = 42/176)

17.6%

(n = 31/176)

3.4%

(n = 6/176)

Subgroup 1

(n = 76)

35.5%

(n = 27/76)

25%

(n = 19/76)

10.5%

(n = 8/76)

0.0%

(n = 0/76)

Subgroup 2

(n = 76)

52.6%

(n = 40/76)

21.1%

(n = 16/76)

26.3%

(n = 20/76)

5.3%

(n = 4/76)

Subgroup 3

(n = 24)

50.0%

(n = 12/24)

29.2%

(n = 7/24)

12.5%

(n = 3/24)

8.3%

(n = 2/24)

^*Considering both radiotherapy (or S-PLND) and systemic therapy (ADT)

^**Appearance of new PCa localization(s) at any imaging procedure including bone scan, CT, whole-body MRI, PET (PSMA or choline or fluciclovine)